Stefan J. Erkeland, PhD

Erkeland-51x53px Assistant Professor, 
 Department of Immunology

 Email contact: s.erkeland@erasmusmc.nl

 Non-coding RNA and Leukemia Research Group (NRL)

Leukemia includes various cancer types of blood-forming cells in the bone marrow (BM) and results in high numbers of malignant non-functional cells (blasts) that overrun normal blood cells. Leukemia represents the 14th and 10th most frequent cause of cancer occurrence and death worldwide, respectively, with more than 437.033 new leukemia cases and 309.006 total leukemia deaths for both sexes estimated in 2018 1,2. Acute leukemia, an aggressive form of this cancer which affects hematopoietic stem and progenitor cells (HSPCs) in the BM, has an incidence of more than 1,000 cases per year in the Netherlands. It can be of lymphoid (T-Acute Lymphoid Leukemia, T-ALL and B-ALL) or myeloid origin (Acute Myeloid Leukemia, AML) and these are considered as heterogeneous groups of cancers 3-7. Some acute leukemia subtypes are characterized by specific genomic aberrations, which largely determines the response to treatment. Overall, the five-year treatment success rate is less than 50% and strongly decreases with the patient’s age. In fact, the overall survival is below 20% in patients older than 60 years and the median survival of AML patients diagnosed at age 65 years or older is only 2,7 months 8-10.

Our research group investigates the functions of small non-coding RNAs, including microRNAs (miRNAs) and small nucleolar RNAs (snoRNAs), in normal and malignant hematopoiesis. MiRNAs are short, non-coding RNA ranging in length from 19 to 23 nucleotides and exert a regulatory effect on cellular transcripts by binding to them in a sequence dependent manner and affecting mRNA stability and translation 11. One typical attribute of miRNA expression is their tissue- and cell-state-dependent nature. The importance of miRNAs in hematopoiesis was implied by demonstrating that deletion of DICER in hematopoietic stem cells, an endonuclease critical for the maturation of miRNAs, leads to loss of hematopoiesis 12. Also, deletion of DICER in hematopoietic progenitors impairs differentiation and cellular functions 13, 14. MiRNAs are deregulated in acute leukemia. We found that some miRNAs, such miR-199 and miR-155 are strong oncogenes and drive leukemic transformation of hematopoietic stem and progenitor cells 15,16. We found that other miRNAs, such as miR-139, are strong tumor suppressors and are frequently downregulated in acute leukemia 16. With my research group I try to understand the functions of these miRNAs in the complex process of oncogenic transformation of hematopoietic stem and progenitor cells towards leukemia.

 

SnoRNAs
SnoRNAs belong to the class of non-coding RNAs, and are critical for normal development of a broad range of organisms, including plants, insects, worms and mammals. SnoRNAs are highly conserved between species and control post-transcriptional RNA processing. In general, their length varies from 60 to 170 nucleotides. SnoRNAs can be divided into three major subfamilies based on structure and function: C/D box snoRNAs (snoRDs), H/ACA box snoRNAs (snoRAs) and Cajal body-specific snoRNAs (scaRNAs) 17. Ribosomes are the protein factories in all cells and consist of a complex of ribosomal RNAs (rRNA) and proteins. Recently published data show that snoRNAs control gene expression in many different ways, amongst other by the regulation of the ribosome 18-20. The best understood function of snoRDs is directing the 2’-O-methyltransferase Fibrillarin to rRNA, whereas scaRNAs guide methylation and pseudouridylation of RNA polymerase II transcribed spliceosomal RNAs U1, U2, U4, U5 and U12. There is emerging evidence that snoRNAs are critically involved in cancer. For instance, a recent pan cancer analysis shows that snoRNAs are aberrantly expressed in 31 types of human solid tumors, including mesothelioma, sarcoma and breast carcinoma, of which at least 46 snoRNAs are clinically relevant 21. Moreover, critical factors in snoRNA biogenesis, such as NOP58, NOP56 and DKC1 are overexpressed in human cancer and associate with poor survival. Deregulated snoRNA expression affects mRNA stability, ribosome structure and function and protein expression. Consequently, this can result in overexpression of oncogenes and/or loss of tumor-suppressor proteins, which are hallmarks of cancer. There is initial evidence that enhanced expression of individual snoRNAs promote different types of human cancer including lung cancer and breast cancer. In addition, snoRNA-derived RNAs (sdRNAs) are abundantly expressed, stable and may have functional activities in normal and malignant cells. Similar to microRNAs (miRNAs), these sdRNAs are bound by Argonaute proteins and may control (post-) transcriptional regulation and translation of target mRNAs. Insights in the regulation of small non-coding RNA expression and downstream controlled molecular networks will provide new options for specific drug targeting, which will be of clinical importance to improve the treatment of leukemia.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
  2. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953.
  3. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136-1152.
  4. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-1320.
  5. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617-1628.
  6. Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134-1142.
  7. Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol. 2015;12(6):344-357.
  8. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-3485.
  9.  Ossenkoppele G, Lowenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767-774.
  10. Gokbuget N. Treatment of older patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):573-579.
  11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
  12. Guo S, Lu J, Schlanger R, et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci U S A. 2010;107(32):14229-14234.
  13. Alemdehy MF, van Boxtel NG, de Looper HW, et al. Dicer1 deletion in myeloid-committed progenitors causes neutrophil dysplasia and blocks macrophage/dendritic cell development in mice. Blood. 2012;119(20):4723-4730.
  14. Alemdehy MF, Erkeland SJ. Stop the dicing in hematopoiesis: what have we learned? Cell Cycle. 2012;11(15):2799-2807.
  15. Alemdehy MF, de Looper HW, Kavelaars FG, et al. MicroRNA-155 induces AML in combination with the loss of C/EBPA in mice. Leukemia. 2016;30(11):2238-2241.
  16. Alemdehy MF, Haanstra JR, de Looper HW, et al. ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation. Blood. 2015;125(25):3937-3948.
  17. Bachellerie JP, Cavaille J, Huttenhofer A. The expanding snoRNA world. Biochimie. 2002;84(8):775-790.
  18. Romano G, Veneziano D, Acunzo M, Croce CM. Small non-coding RNA and cancer. Carcinogenesis. 2017;38(5):485-491.
  19. Zhong F, Zhou N, Wu K, et al. A SnoRNA-derived piRNA interacts with human interleukin-4 pre-mRNA and induces its decay in nuclear exosomes. Nucleic Acids Res. 2015;43(21):10474-10491.
  20. Baxter-Roshek JL, Petrov AN, Dinman JD. Optimization of ribosome structure and function by rRNA base modification. PLoS One. 2007;2(1):e174.
  21. Gong J, Li Y, Liu CJ, et al. A Pan-cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer. Cell Rep. 2017;21(7):1968-1981.

 Current Projects   

  1. Targeting miR-139, a novel tumor suppressor in acute myeloid leukemia (KWF-grant, 10948).
  2. Small non-coding RNAs in immunological diseases, H2020-SC1-2016-2017, ImmunAID (personalised medicine), #779295.
  3. Harnessing miRNAs to restore CTL immunity in cancer Worldwide Cancer Research grant (16-1153) (in collaboration with prof. dr. P.Katsikis).
  4. Unraveling the functions of microRNAs and RNA binding proteins in leukemia.
  5. Profiling and functional investigation of (oncogenic) snoRNAs in the development of acute  leukemia.

 

Fig. A) Cumulative survival of mice transplanted with hematopoietic stem and progenitor cells expressing EGFP with, miR-199a (n=5), (p<0.0005 compared to EV (EGFP only) n=9), miR-106 (n=4) (a non-oncogenic miRNA that promotes myeloid progenitor expansion),  or secondary recipients of miR-199a leukemia cells (n=7)(p<0,0005 compared to EV). B) Micrographs showing the morphology of leukemia blasts in the spleen.

 

 

   

 

 

 

  

 Dr.S. Erkeland: training, positions and research

BSc
Title(s), initial(s), surname: Dr. S.J. Erkeland
University/College of Higher Education: Hogeschool West-Brabant, the Netherlands
Date: Jun 06, 1995
Main subject: Biochemistry

Doctorate
University: Erasmus University Rotterdam, the Netherlands
Starting date: 01/10/1999
Date of PhD award: Apr 27, 2005
Promotor: Prof.dr. I.P. Touw and Prof.dr. B. Löwenberg
Thesis title: Identification, Function and Clinical Relevance of Mouse Myeloid Leukemia Genes

 Position Period
(date - date)
 FTE Type of position Institution
 Post-docMay 2005 - Apr 2007 1.0 Fixed termMassachusetts Institute of Technology,
Cambridge, USA
 Post-docMay 2007 - Nov 2007 1.0 Fixed termErasmus MC,
Hematology department, Rotterdam, the Netherlands
 Research group leaderDec 2007 - May 2015 1.0 Fixed termErasmus MC-Cancer Institute,
Hematology department, Rotterdam, the Netherlands
 Research group leaderJun 2015 -  Nov 2017 1.0 PermanentErasmus MC,
Immunology department, Rotterdam, the Netherlands
 Assistant professor (UHD)Dec 2017 - 1.0 PermanentErasmus MC,
Immunology department, Rotterdam, the Netherlands

Brief summary of research

As a post-doc awarded with a KWF-fellowship, I’m trained in the lab of Nobel prize laureate prof. Sharp to investigate the role of small non-coding RNAs (sncRNA) in cancer. The past 12 years, I have continued my research in this exciting field as an independent investigator. My training in excellent laboratories and long-term experience in acute leukemia research and small non-coding RNA have helped me to receive more than €4.700.000,00 for my projects, including a highly competitive VENI award and competitive KWF grants. Together with my team and (inter)national collaborators, I have developed unique mouse models, novel molecular protocols and state-of-the-art technology enabling me to investigate the complex activities of sncRNA in leukemia development. These tools and approaches are also used by (inter)national collaborators and have resulted in exciting innovative findings on the functions of small non-coding RNAs in cancer. These data have been published in high impact journals such as Blood, Leukemia and Cell Stem Cell. I unraveled microRNA-controlled oncogenic mechanisms in the transition of pre-leukemic cells towards acute leukemia, which was a break-through in the field. In my research line, I am investigating the contributions of small nucleolar RNAs (snoRNAs) to leukemia development, which are novel players in human cancer. My preliminary data show that snoRNAs are aberrantly expressed in leukemia and may be critical drivers of oncogenesis. Notably, small non-coding RNAs are interesting targets for drug development. Our findings need further investigation and may ultimately result in new treatment options.

 Group members

Stefan Erkeland, PhD, Research Group leader, Assistant Professor 
Antoinette van Hoven-Bijen, BSc., Senior Technician 
Christiaan Stavast, MSc., PhD student
Iris van Zuijen, MSc., Technician
Noud Verstappen, HLO student, Avans University of Applied Sciences
Stijn van den Broek, HLO student, University of Applied Sciences, Utrecht

Previous PhD students in the NRL group:

Dr. Mir Farshid Alemdehy
Thesis: MicroRNAs in Normal and Malignant Myelopoiesis, defense March 11, 2015

Dr. Mohsen Ghanbari
Thesis: The role of microRNAs in Age-related disorders: from population-based genetic studies to experimental validation, defense July 05, 2017

 Positions

 

 

 

 

 

   

   

 
We are always looking for new talent. Please contact us when you are searching for an internship (MSc. or BSc.) or job position in an exciting field.  

 Selected Publications

(See for all publications Erkeland S in PubMed)

A functional variant in the miR-142 promoter modulating its expression and conferring risk of Alzheimer disease.
Mohsen Ghanbari, Shashini T. Munshi, Buyun Ma, Bas Lendemeijer, Sakshi Bansal, Hieab H. Adams, Wenshi Wang, Kerstin Goth, Denise E. Slump, Mirjam C.G.N van den Hout, Wilfred F.J. van IJcken, Saverio Bellusci, Qiuwei Pan, Stefan J. Erkeland, Femke M.S. de Vrij, Steven A. Kushner, M. Arfan Ikram.
Human Mutation. 2019 Jul.

The interplay between critical transcription factors and microRNAs in the control of normal and malignant myelopoiesis.
Stavast CJ, Leenen PJM, Erkeland SJ.
Cancer Lett. 2018 Jul 28;427:28-37.

A systematic analysis highlights multiple long non-coding RNAs associated with cardiometabolic disorders.
Ghanbari M, Peters MJ, de Vries PS, Boer CG, van Rooij JGJ, Lee YC, Kumar V, Uitterlinden AG, Ikram MA, Wijmenga C, Ordovas JM, Smith CE, van Meurs JBJ, Erkeland SJ, Franco OH, Dehghan A.
J Hum Genet. 2018 Apr;63(4):431-446.

The Transcription Factor T-Bet Is Regulated by MicroRNA-155 in Murine Anti-Viral CD8+ T Cells via SHIP-1.
Hope JL, Stairiker CJ, Spantidea PI, Gracias DT, Carey AJ, Fike AJ, van Meurs M, Brouwers-Haspels I, Rijsbergen LC, Fraietta JA, Mueller YM, Klop RC, Stelekati E, Wherry EJ, Erkeland SJ, Katsikis PD.
Front Immunol. 2017 Dec 6;8:1696.

A genome-wide scan for microRNA-related genetic variants associated with primary open-angle glaucoma.
Mohsen Ghanbari1, Adriana I. Iglesias, Henriët Springelkamp, Cornelia van Duijn, M. Arfan Ikram, Abbas Dehghan, Stefan J. Erkeland, Caroline C.W. Klaver, Magda A. Meester-Smoor.
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5368-5377.

Genetic variants in microRNAs and their binding sites within gene 3'UTRs associate with susceptibility to age-related macular degeneration.
Ghanbari M, Erkeland SJ, Xu L, Colijn JM, Franco OH, Dehghan A, Klaver CCW, Meester-Smoor MA.
Hum Mutat. 2017 Jul;38(7):827-838.

MicroRNA-155 induces AML in combination with the loss of C/EBPA in mice.
Alemdehy MF, de Looper HW, Kavelaars FG, Sanders MA, Hoogenboezem R, Löwenberg B, Valk PJ, Touw IP, Erkeland SJ.
Leukemia. 2016 Nov;30(11):2238-2241.

Ectopic miR-125a Expression Induces Long-Term Repopulating Stem Cell Capacity in Mouse and Human Hematopoietic Progenitors.
Wojtowicz EE, Lechman ER, Hermans KG, Schoof EM, Wienholds E, Isserlin R, van Veelen PA, Broekhuis MJ, Janssen GM, Trotman-Grant A, Dobson SM, Krivdova G, Elzinga J, Kennedy J, Gan OI, Sinha A, Ignatchenko V, Kislinger T, Dethmers-Ausema B, Weersing E, Alemdehy MF, de Looper HW, Bader GD, Ritsema M, Erkeland SJ, Bystrykh LV, Dick JE, de Haan G.
Cell Stem Cell. 2016 Sep 1;19(3):383-96.

Genome-wide identification of microRNA-related variants associated with risk of Alzheimer's disease.
Ghanbari M, Ikram MA, de Looper HW, Hofman A, Erkeland SJ, Franco OH, Dehghan A.
Sci Rep. 2016 Jun 22;6:28387.

An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation.
Avellino R, Havermans M, Erpelinck C, Sanders MA, Hoogenboezem R, van de Werken HJ, Rombouts E, van Lom K, van Strien PM, Gebhard C, Rehli M, Pimanda J, Beck D, Erkeland S, Kuiken T, de Looper H, Gröschel S, Touw I, Bindels E, Delwel R.
Blood. 2016 Jun 16;127(24):2991-3003.

Genetic Variants in MicroRNAs and Their Binding Sites Are Associated with the Risk of Parkinson Disease.
Ghanbari M, Darweesh SK, de Looper HW, van Luijn MM, Hofman A, Ikram MA, Franco OH, Erkeland SJ, Dehghan A.
Hum Mutat. 2016 Mar;37(3):292-300.

Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.
Nowek K, Sun SM, Dijkstra MK, Bullinger L, Döhner H, Erkeland SJ, Löwenberg B, Jongen-Lavrencic M.
Leukemia. 2016 Feb;30(2):303-9.

Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.
Nowek K, Sun SM, Bullinger L, Bindels EM, Exalto C, Dijkstra MK, van Lom K, Döhner H, Erkeland SJ, Löwenberg B, Jongen-Lavrencic M.
Leukemia. 2016 Jan;30(1):229-37.

Genetic Variations in MicroRNA-Binding Sites Affect MicroRNA-Mediated Regulation of Several Genes Associated With Cardio-metabolic Phenotypes.
Ghanbari M, Franco OH, de Looper HW, Hofman A, Erkeland SJ, Dehghan A.
Circ Cardiovasc Genet. 2015 Jun;8(3):473-86.

ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation.
Alemdehy MF, Haanstra JR, de Looper HW, van Strien PM, Verhagen-Oldenampsen J, Caljouw Y, Sanders MA, Hoogenboezem R, de Ru AH, Janssen GM, Smetsers SE, Bierings MB, van Veelen PA, von Lindern M, Touw IP, Erkeland SJ.
Blood. 2015 Jun 18;125(25):3937-48.

The association of common polymorphisms in miR-196a2 with waist to hip ratio and miR-1908 with serum lipid and glucose levels.
Mohsen Ghanbari, Sanaz Sedaghat, Hans de Looper, Albert Hofman, Stefan J. Erkeland, Oscar H Franco, Abbas Dehghan.
Obesity. 2015; 23(2):495 - 503.

A genetic variant in the seed region of miR-4513 shows pleiotropic effects on lipid and glucose homeostasis, blood pressure, and coronary artery disease.
Ghanbari M, de Vries PS, de Looper H, Peters MJ, Schurmann C, Yaghootkar H, Dörr M, Frayling TM, Uitterlinden AG, Hofman A, van Meurs JB, Erkeland SJ, Franco OH, Dehghan A.
Hum Mutat. 2014 Dec;35(12):1524-31.

Stop the Dicing in Hematopoiesis; what have we learned?
Alemdehy MF, Erkeland SJ. (invited review + experimental data)
Cell Cycle. 2012; 11(15): 2799 - 2807.

MicroRNAs: key players of normal and malignant myelopoiesis.
Alemdehy MF, Erkeland SJ. (invited review)
Curr Opin Hematol. 2012; 19:261-7.

Dicer1 deletion in myeloid-committed progenitors causes neutrophil dysplasia and blocks macrophage/dendritic cell development in mice.
Alemdehy MF, van Boxtel NG, de Looper HW, van den Berge IJ, Sanders MA, Cupedo T, Touw IP, Erkeland SJ.
Blood. 2012; 119:4723-30.

Retroviral integration mutagenesis in mice and comparative analysis in human AML identify reduced PTP4A3 expression as a prognostic indicator.
Beekman R, Valkhof M, Erkeland SJ, Taskesen E, Rockova V, Peeters JK, Valk PJ, Lowenberg B, Touw IP.
PLoS One. 2011; 6:e26537.

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice.
Meenhuis A, van Veelen PA, de Looper H, van Boxtel N, van den Berge IJ, Sun SM, Taskesen E, Stern P, de Ru AH, van Adrichem AJ, Demmers J, Jongen-Lavrencic M, Lowenberg B, Touw IP, Sharp PA, Erkeland SJ.
Blood. 2011; 118:916-25.

Transition of highly specific microRNA expression patterns in association with discrete maturation stages of human granulopoiesis.
Sun SM, Dijkstra MK, Bijkerk AC, Brooimans RA, Valk PJ, Erkeland SJ, Lowenberg B, Jongen-Lavrencic M.
Br J Haematol. 2011; 155:395-8.

The gene encoding thioredoxin-interacting protein (TXNIP) is a frequent virus integration site in virus-induced mouse leukemia and is overexpressed in a subset of AML patients. Erkeland SJ, Palande KK, Valkhof M, Gits J, Danen-van Oorschot A, Touw IP.
Leuk Res. 2009; 33:1367-71.

Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7.
Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR.
EMBO J. 2009; 28:347-58.

A system for Cre-regulated RNA interference in vivo.
Stern P, Astrof S, Erkeland SJ, Schustak J, Sharp PA, Hynes RO.
Proc Natl Acad Sci U S A. 2008; 105:13895-900.

Targeted deletion reveals essential and overlapping functions of the miR-17~92 family of miRNA clusters.
Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T.
Cell. 2008; 132:875-86.

Suppression of non-small cell lung tumor development by the let-7 microRNA family.
Kumar MS, Erkeland SJ (shared first authorship), Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T.
Proc Natl Acad Sci U S A. 2008; 105:3903-8.

Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor.
Irandoust MI, Aarts LH, Roovers O, Gits J, Erkeland SJ, Touw IP.
EMBO J. 2007; 26:1782-93.

Touw IP, Erkeland SJ.
Retroviral insertion mutagenesis in mice as a comparative oncogenomics tool to identify disease genes in human leukemia.
Mol Ther. 2007; 15:13-9. (invited review).

Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling.
Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP.
Oncogene. 2007; 26:1985-94.

Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia.
Erkeland SJ, Verhaak RG, Valk PJ, Delwel R, Lowenberg B, Touw IP.
Cancer Res. 2006; 66:622-6.

Wolfler A, Erkeland SJ, Bodner C, Valkhof M, Renner W, Leitner C, Olipitz W, Pfeilstocker M, Tinchon C, Emberger W, Linkesch W, Touw IP, Sill H.
A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome.
Blood. 2005; 105:3731-6.

Large-scale identification of disease genes involved in acute myeloid leukemia.
Erkeland SJ, Valkhof M, Heijmans-Antonissen C, van Hoven-Beijen A, Delwel R, Hermans MH, Touw IP.
J Virol. 2004; 78:1971-80.

Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis.
Danen-Van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams JP, Mumberg D, Noteborn MH.
J Biol Chem. 2003; 278:27729-36.

Granulocyte colony-stimulating factor and its receptor in normal hematopoietic cell development and myeloid disease.
van de Geijn GJ, Aarts LH, Erkeland SJ, Prasher JM, Touw IP.
Rev Physiol Biochem Pharmacol. 2003; 149:53-71.

The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation.
Erkeland SJ, Valkhof M, Heijmans-Antonissen C, Delwel R, Valk PJ, Hermans MH, Touw IP.
Blood. 2003; 101:1111-7.

Bcl-2 and Bax proteins are present in interphase nuclei of mammalian cells.
Hoetelmans R, van Slooten HJ, Keijzer R, Erkeland SJ, van de Velde CJ, Dierendonck JH.
Cell Death Differ. 2000; 7:384-92.

The effect of Bcl-2 on Apoptin in 'normal' vs transformed human cells.
Danen-Van Oorschot AA, Zhang Y, Erkeland SJ, Fischer DF, van der Eb AJ, Noteborn MH.
Leukemia. 1999; 13 Suppl 1:S75-7.

The localization of bullous pemphigoid antigen 180 (BP180) in hemidesmosomes is mediated by its cytoplasmic domain and seems to be regulated by the beta4 integrin subunit.
Borradori L, Koch PJ, Niessen CM, Erkeland SJ, van Leusden MR, Sonnenberg A.
J Cell Biol. 1997; 136:1333-47. 8.784.